The treatment of type 2 diabetes has evolved over the past decade, and incretin-based drugs, including dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1)
glucagon-like peptide-1
glucagon-like peptide-1
Do DPP4 Inhibitors and GLP-1 Receptor Agonists Increase the Risk of Intestinal Obstruction?
Do DPP4 Inhibitors and GLP-1 Receptor Agonists Increase the Risk of Intestinal Obstruction?
